{"name":"Yunpeng Liu","slug":"yunpeng-liu","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOZENQTlJndm1oa2NKbXRBd2NtTDJPR2ZHMzR3NTdValMtOHZmOUc5LUZxMExUQ1B6QzV2bFJaVkpEUHQ5bVNmNHpVRW1DdnF3Uy1MRGRjX3pSajJkV2FWRlhhcE8zLUdOaFQtdHJYV19kb3lMeUtfUVEtdlI0SzExU19XMWx5MkhrRzVQNDF3?oc=5","date":"2025-12-22","type":"pipeline","source":"Frontiers","summary":"In vivo detection of HER2-positive breast cancer and sentinel lymph node metastasis using activatable ICG-conjugated Trastuzumab - Frontiers","headline":"In vivo detection of HER2-positive breast cancer and sentinel lymph node metastasis using activatable ICG-conjugated Tra","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1HT3lvQTdvMF9JaXFuSzlpaWtLOTJoN0tHWFh0OTJXZ3EwdXd6d293dHlLY0t5dE16dkpSaTNtVWNqSEZJQkxfNGtTVXlpN3NVZ1VsQjdKZ1VvQ0FLV0tB?oc=5","date":"2024-09-12","type":"trial","source":"nature.com","summary":"First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors - nature.com","headline":"First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE40emM2bTByU3Ewa3pFel95TGNsWFRjb18zNlRNU0g1ZUYydWx6VjhtRHljOXd3LWFwSWZxeTZKdEY4ZjdBbmFoTVhUQ2FkOHdNNDI0YkdPZ2c2Uko2djg3bFlFOVR5WE1MS0E?oc=5","date":"2022-09-02","type":"pipeline","source":"Wiley Online Library","summary":"Results from the IMpower132 China cohort: Atezolizumab plus platinum-based chemotherapy in advanced non-small cell lung cancer - Wiley Online Library","headline":"Results from the IMpower132 China cohort: Atezolizumab plus platinum-based chemotherapy in advanced non-small cell lung ","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}